Incyte Corporation
Incyte Corporation (INCY) Revenue
Annual & quarterly revenue history · segment & region breakdown
INCY · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsIncyte Corporation trailing twelve-month (TTM) revenue is $5.36B, an increase of 21.22% year-over-year from $5.14B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $5.14B | +$0.90B | +21.22% |
| 2024-12-31 | $4.24B | +$0.55B | +14.76% |
| 2023-12-31 | $3.70B | +$0.30B | +8.87% |
| 2022-12-31 | $3.39B | +$0.41B | +13.67% |
| 2021-12-31 | $2.99B | +$0.32B | +11.98% |
| 2020-12-31 | $2.67B | +$0.51B | +23.53% |
| 2019-12-31 | $2.16B | +$0.28B | +14.71% |
| 2018-12-31 | $1.88B | +$0.35B | +22.50% |
| 2017-12-31 | $1.54B | +$0.43B | +38.93% |
| 2016-12-31 | $1.11B | +$0.35B | +46.70% |
Compare revenue vs peers
BiotechnologyCompare INCY revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Incyte Corporation receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Incyte Corporation reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Incyte Corporation's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
INCY revenue · 4 questionsINCY's trailing twelve-month (TTM) revenue is $5.36B. That is an increase of 21.22% year-over-year from $5.14B in FY2025.
▸ Source: FMP · Incyte Corporation SEC filings · GAAP · Incyte Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026